研究活動情報

• ペインクリニックのすすめ 痛みの研究と臨床の架け橋

  岡田 卓也, 上野 喬平, 野村 有紀, 西原 侑紀, 佐藤 仁昭

  (一社)日本ペインクリニック学会, 2025年09月, 日本ペインクリニック学会誌, 32(プログラム号) (プログラム号), DM - 4, 日本語


• Resting-state brain functional connectivity in patients with chronic intractable pain who respond to spinal cord stimulation therapy.

  Kyohei Ueno, Yoshitetsu Oshiro, Shigeyuki Kan, Yuki Nomura, Hitoaki Satou, Norihiko Obata, Satoshi Mizobuchi

  BACKGROUND: Spinal cord stimulation (SCS) is widely accepted as a useful treatment for patients with intractable chronic pain. However, its effectiveness varies between individuals. Therefore, a tool for evaluating its effectiveness in advance is eagerly awaited. We examined whether resting-state functional magnetic resonance imaging as a diagnostic and prognostic tool can predict responsiveness to SCS. METHODS: Twenty-nine patients with intractable chronic pain participated in this study. Participants were divided into responder and non-responder groups based on a pain relief rate after SCS trials. All participants underwent resting-state functional magnetic resonance imaging scans before the SCS trials. We searched for functional connectivity that differed significantly in strength between the two groups and was correlated with pain relief rate. We conducted receiver operating characteristic (ROC) analysis and a one-sample proportion test to determine the cut-off value and evaluate the predictive power of the functional connectivity-based prediction model. RESULTS: In total, 14 and 15 participants were assigned to the responder and non-responder groups, respectively. Functional connectivity between the middle anterior cingulate cortex and precuneus/posterior cingulate cortex showed significant between-group differences and a significant negative correlation with the pain relief rate. Moreover, this functional connectivity could accurately predict SCS responsiveness greater than chance (sensitivity: 71%; specificity: 87%; area under the curve: 0.814; P<0.001). CONCLUSIONS: For patients with intractable chronic pain, functional connectivity between the middle anterior cingulate cortex and precuneus/posterior cingulate cortex is a promising candidate biomarker to estimate responsiveness to spinal cord stimulation before treatment.

  2024年11月, British journal of anaesthesia, 英語, 国際誌

  [査読有り]

  研究論文（学術雑誌）

  神戸大学リポジトリ（Kernel）へのリンク


• 迷走神経及び舌咽神経領域の帯状疱疹関連痛の1例

  西原 侑紀, 溝渕 知司, 佐藤 仁昭, 野村 有紀, 上野 喬平

  (一社)日本ペインクリニック学会, 2024年06月, 日本ペインクリニック学会誌, 31(プログラム号) (プログラム号), 165 - 165, 日本語


• 当院における抜歯後感覚障害に対する星状神経節ブロックの効果の検討

  上野 喬平, 佐藤 仁昭, 西原 侑紀, 野村 有紀, 溝渕 知司

  (一社)日本ペインクリニック学会, 2024年06月, 日本ペインクリニック学会誌, 31(プログラム号) (プログラム号), 298 - 298, 日本語


• Improvement of sleep and pain with lemborexant administration in patients with chronic pain: a retrospective observational study.

  Kyohei Ueno, Hitoaki Sato, Yuki Nomura, Norihiko Obata, Satoshi Mizobuchi

  OBJECTIVE: Patients with chronic pain often have sleep disturbances, and many patients receive sleep medications in addition to analgesics. Although there have been scattered reports of negative pain-sleep interactions, only a few reports have investigated the efficacy of sleep medication interventions in patients with chronic pain for improving sleep disturbances and reducing pain. We retrospectively examined whether lemborexant, an orexin receptor antagonist, is effective in improving sleep disturbances and reducing pain in patients with chronic pain. This study was approved by the Ethics Committee of our hospital. METHODS: The subjects were 26 patients with chronic pain undergoing treatment at our pain clinic between July 2021 and March 2022, who had been diagnosed with insomnia, with an Athens Insomnia Scale (AIS) score of ≥6 and had been started on lemborexant. The AIS score and pain score (Numeric Rating Scale [NRS]) before and after 2 and 4 weeks of starting lemborexant were investigated. RESULTS: Patients who were already taking other sleep medications, such as benzodiazepines were switched to 5 mg of lemborexant after all the other sleep medications were discontinued. Those who had not yet used sleeping pills were started on 5 mg of lemborexant. During the study course, the dose of lemborexant was adjusted at the discretion of the attending physician, based on improvement of insomnia symptoms and secondary symptoms, such as daytime sleepiness and lightheadedness. The study finally included 21 patients, excluding 5 who could not continue taking lemborexant due to side effects, such as lightheadedness. The AIS scores significantly improved, decreasing from baseline (mean ± standard deviation: 12.5 ± 4.9) to 2 weeks (7.8 ± 3.1) and 4 weeks (5.3 ± 2.9) after the start of lemborexant. No significant difference was observed in the degree of improvement in sleep disturbance between patients with or without previous sleep medications, and there was also no statistically significant improvement in the NRS score before (6.1 ± 2.7) and after 2 weeks (5.5 ± 2.3) and 4 weeks (5.9 ± 2.2) from treatment initiation.

  2024年02月, Pain medicine (Malden, Mass.), 25(2) (2), 139 - 143, 英語, 国際誌

  [査読有り]

  研究論文（学術雑誌）


• 試験的脊髄刺激療法が奏効した慢性神経障害性疼痛患者における安静時脳機能結合の特徴

  上野 喬平, 大城 宣哲, 佐藤 仁昭, 野村 有紀, 寒 重之, 溝渕 知司

  (一社)日本疼痛学会, 2023年12月, PAIN RESEARCH, 38(Suppl.) (Suppl.), S61 - S61, 日本語

• 多剤服用となっていた化学療法誘発性末梢神経障害性疼痛患者に対し入院による薬剤調整

  西原侑紀, 溝渕知司, 佐藤仁昭, 野村有紀, 上野喬平, 岡田卓也

  2025年, 日本ペインクリニック学会誌(Web), 32(2) (2)


• 迷走神経及び舌咽神経領域の帯状疱疹関連痛の1例

  西原侑紀, 溝渕知司, 佐藤仁昭, 野村有紀, 上野喬平

  2024年, 日本ペインクリニック学会誌(Web), 31(program) (program)


• 当院における抜歯後感覚障害に対する星状神経節ブロックの効果の検討

  上野喬平, 佐藤仁昭, 西原侑紀, 野村有紀, 溝渕知司

  2024年, 日本ペインクリニック学会誌(Web), 31(program) (program)


• 試験的脊髄刺激療法が奏効した慢性神経障害性疼痛患者における安静時脳機能結合の特徴

  上野喬平, 大城宣哲, 佐藤仁昭, 野村有紀, 寒重之, 溝渕知司

  2023年, Pain Research (Web), 38(Supplement) (Supplement)

• 慢性高血糖マウスのインスリン抵抗性と好中球機能からみた新しい術前血糖管理法の開発

  上野 喬平

  日本学術振興会, 科学研究費助成事業, 若手研究, 神戸大学, 2020年04月01日 - 2023年03月31日

  慢性高血糖マウスにおける好中球機能改善のメカニズムを明らかにし、至適な術前血糖管理期間を調査することが本研究の目的である。 昨年度は先行研究の結果からインスリン抵抗性改善と好中球機能改善の推移を検討するために、高血糖マウスを作成し、血糖介入を行い、フローサイトメトリーによる好中球機能(好中球貪食能および活性酸素産生能)の評価を行った。さらに、慢性高血糖マウスに対する血糖管理が好中球機能改善に寄与するメカニズムの解明のため、ウエスタンブロット法とフローサイトメトリーによる好中球内の分子活性(PI3K-Akt経路やPKC経路、最終糖化産物(AGEs))を評価した。